Compare Global X FTSE Southeast Asia ETF (ASEA) vs CVS Health Corp (CVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs CVS Health Corp — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.65, while CVS Health Corp trades at $104.58 (market cap $132.89B). The key difference: CVS Health Corp pays a 2.55% dividend while Global X FTSE Southeast Asia ETF pays none. Which is the better fit depends on your goals.
| ASEA | CVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $20.65 | $104.81 |
52-Week Low | $16.31 | $58.75 |
Market Cap | — | $132.89B |
Enterprise Value | — | $199.43B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
CVS Health trades at $104.15, up 1.3% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $2.57 exceeding expectations of $2.18. Revenue growth remains robust at $402.07B for 2025, though net margins have compressed to 0.72%. Recent dividend declarations and positive media coverage highlight the company's stable cash flow generation and market positioning.
CVS presents a compelling investment case with 84.6% analyst buy ratings and a $107.29 consensus target offering 3% upside. However, investors face risks from declining profitability margins, elevated debt levels at 25.48% debt-to-asset ratio, and competitive pressures in the healthcare sector. The stock's current valuation at 45.68 P/E requires careful monitoring of margin improvement initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
